Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies
Authors' conclusion
Premenopausal women under HDTs are at high risk of VFs in relationship with high BMI, densitometric diagnosis of osteoporosis, preexisting VFs, and family history of osteoporotic fractures. Vertebral fractures in this setting might be effectively prevented by bisphosphonates or denosumab.
Study context
- Population
- Premenopausal women with early breast cancer (BC) undergoing hormone-deprivation therapies
- Participants
- 306 women
- Exposure
- Bone-active drugs vs no treatment
- Treatedn = 237
- Untreatedn = 69reference
- Outcome
- New morphometric vertebral fractures (VFs)
- Follow-up
- After at least 24 months
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
New VFs · 47.0 ± 20.1 months
P < 0.001
- New vertebral fractures (VFs) overall
- 16 women (5.2%)
- Anti-fracture effectiveness, OR after correction for BMI
- 0.03; P < .001
- OR after correction for family history of fractures
- 0.03; P < .001
- OR after correction for chemotherapy-induced menopause
- 0.04; P < .001
- OR after correction for preexisting VFs
- 0.01; P < .001
Observational data: associations, not effects.
Further findings
Factors associated with VF risk
- Obesity
- OR 3.87, P = .028
- Family history of hip fractures or VFs
- OR 3.21, P = .040
- Chemotherapy-induced menopause
- OR 6.48, P < .001
- Preexisting VFs
- OR 25.36, P < .001
- Baseline T-score ≤−2.5 SD at any site
- OR 4.14, P = .036
- Change in lumbar bone mineral density (BMD)
- OR 0.94, P = .038
- Change in total hip BMD
- OR 0.88, P < .001
Original publication
Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies. Eur J Endocrinol. Published 26 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →